SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2025-02-12 (businessupturn.com)
Zydus signs exclusive agreement with Synthon for a novel 505(B)(2) oncology product for US market |
Zydus Lifesciences Ltd., a leading global healthcare company, has signed an exclusive development, licensing, supply, and commercialization agreement with Synthon BV, Netherlands. This collaboration focuses on a novel 505(B)(2) oncology product for an undisclosed target, marking a significant advancement in cancer treatment. Under the agreement, Synthon will handle the development, manufacturing, and supply of the […]
Read more
2013-04-03 (europeanpharmaceuticalreview.com)
Synthon chooses Avacta’s Optim 1000 for high throughput formulation studies
Pharmaceutical developers at Synthon have chosen an Optim 1000 high throughput, micro-volume protein analysis system...
Read more
(rediff.com)
Zydus Lifesciences Partners with Synthon for New Cancer Treatment: Moneynews
Zydus Lifesciences and Synthon BV have partnered to develop and commercialize a novel 505(B)(2) oncology product for the US market, aiming to provide patients with alternative treatment options for a high unmet need therapy area.
Read more
(indiatimes.com)
Zydus ties up with Dutch firm for novel cancer drug -
India Business News: Zydus Lifesciences has partnered with Synthon BV in a deal to develop, license, supply, and commercialize a novel oncology drug in the US. The agreeme
Read more